Physician profile
Yvette Brooks
NPI 1922515667
$1,162.96
in general payments reported to CMS, 2019-2025
12 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.74 · 2022: $551 · 2023: $37.08 · 2024: $163 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489 · Travel and Lodging: $36.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.32 |
| Travel and Lodging | $36.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.75 | 2024-2025 | |
| Novo Nordisk INC | $246.62 | 2022-2023 | Ozempic, Rybelsus |
| Galderma Laboratories, L.P. | $119.96 | 2022 | |
| Lilly USA, LLC | $119.65 | 2022-2023 | Mounjaro |
| Merz North America, INC. | $108.76 | 2024 | |
| Millicent US INC | $51.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.79 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $27.64 | 2022 | |
| Amarin Pharma, INC. | $18.82 | 2022 | |
| Therapeuticsmd, INC. | $17.87 | 2021 | |
| Esperion Therapeutics, INC. | $17.55 | 2021 | |
| Sanofi Pasteur INC. | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.